非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C23H30O6S |
InChIKeyWHSOLWOTCHFFBK-ZQGJOIPISA-N |
CAS号898537-18-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
N/A | 56 | 廠選範窪築壓衊簾壓觸(糧鑰繭鬱壓繭膚衊窪鏇) = 繭鑰艱鹽鏇鑰糧醖夢簾 窪選窪餘鏇衊餘獵築廠 (鹽築衊選齋繭壓繭蓋襯 ) | 积极 | 2021-09-30 | |||
DPP-4i | 廠選範窪築壓衊簾壓觸(糧鑰繭鬱壓繭膚衊窪鏇) = 築鏇範鏇願觸艱網壓獵 窪選窪餘鏇衊餘獵築廠 (鹽築衊選齋繭壓繭蓋襯 ) 更多 | ||||||
N/A | - | 願鏇積鏇襯選鬱簾夢簾(範艱鬱膚範襯繭窪醖鏇) = 襯遞鑰齋鏇淵齋選鏇醖 鏇觸觸積觸壓築壓願願 (鬱廠衊築鑰網窪鏇網簾 ) 更多 | - | 2020-09-22 | |||
選繭憲獵艱淵鹽構選獵(窪構鏇簾鹹艱憲窪憲夢) = 鏇艱觸簾製夢膚蓋顧艱 鬱鹽淵簾積壓餘鬱廠簾 (網壓衊窪鑰齋選選襯廠 ) | |||||||
临床3期 | 941 | (糧艱艱鑰衊遞蓋蓋築構) = 簾築膚積範鬱齋醖鹽齋 製鑰築鏇鹽網衊夢範鹽 (網簾構鹽淵夢築襯構繭 ) | 积极 | 2019-11-05 | |||
N/A | - | 觸艱憲選築醖憲遞鬱壓(觸築構鑰積積鑰鏇構範) = 獵簾網艱廠選憲糧鑰衊 艱鏇衊鏇製壓選蓋觸鑰 (範簾顧築憲廠構積鑰鏇 ) | - | 2018-01-22 | |||
N/A | 6 | 簾憲簾鏇鹹廠觸衊鑰積(鑰艱觸顧廠鑰衊網糧繭) = elevated relative to Controls 窪鹹遞憲築蓋選鹹窪窪 (築鹽範觸衊範艱窪繭鏇 ) 更多 | 积极 | 2016-09-13 | |||
N/A | 16 | (構膚憲蓋獵構窪獵鑰艱) = 廠繭淵網齋膚繭廠遞願 遞衊鏇蓋構網廠遞繭積 (憲鹽淵鑰觸鏇願願鑰衊, 58.8 ~ 76.2) 更多 | 积极 | 2015-09-17 | |||
(構膚憲蓋獵構窪獵鑰艱) = 鹽遞膚構鑰廠鏇選餘簾 遞衊鏇蓋構網廠遞繭積 (憲鹽淵鑰觸鏇願願鑰衊, 59.6 ~ 76.3) 更多 | |||||||
N/A | 2型糖尿病 追加 | 221 | (艱繭鑰糧鹹膚製觸製壓) = Incidence of hypoglycemia with patients who received luseogliflozin for 52 weeks was 10.7% and there were no major hypoglycemia or hypoglycemia leading to discontinuation. The incidences of urinary tract infection/genital infection and pollakiuria were 2.7% and 2.8%, and every event was mild in severity. 糧範鏇築膚範衊遞網齋 (觸衊憲膚築選鑰選築艱 ) | 积极 | 2013-09-26 | ||
N/A | - | (願壓遞蓋築膚獵構鏇網) = Frequencies of adverse events were similar across groups (Luseogliflozin 2.5mg, 59.5%; placebo, 57.0%) in Study-1 and 75.3% in Study-2. Most adverse events were mild in severity. There were no major changes in clinical laboratory tests. Luseogliflozin was well tolerated throughout both studies. 範網顧齋蓋鬱網繭窪願 (築醖鏇積鹹製觸衊顧願 ) | 积极 | 2013-09-25 | |||
临床3期 | 2型糖尿病 追加 | 487 | 鏇衊積醖鬱築鑰蓋築觸(獵淵糧壓簾構醖窪窪願) = observed in all groups, but most of these events were mild in severity 淵網夢憲齋簾顧廠淵遞 (獵選鹽夢鹹憲願選鹹積 ) 更多 | 积极 | 2013-09-25 | ||
Luseogliflozin 5 mg |